DESCRIPTION: (as per abstract) The objective is to develop sufficient knowledge
of the molecular mechanisms by which LMP1 alters cell growth and of the effects
of inhibiting those mechanisms so as to design screens for inhibitors that
might be effective in treating EBV associated malignancies. The specific goals
are to: (1) Use recombinant EBV based genetics to clarify the role of specific
LMP1 amino acids (aa) in primary B lymphocyte growth transformation. The focus
will be on aa between transformation effector site 1 (TES1) and TES2, TES1,
TES2 and aa within the transmembrane domains. (2) Determine whether LMP1
signals through interactions with other receptors. LMP1 association with
membrane rafts, with cytoskeletal elements, and with other membrane proteins,
particularly TNFRs, will be investigated using genetic, biochemical, and
physiological approaches. (3) Determine the mechanisms by which N-terminally
truncated IkB causes apoptosis of EBV transformed cells so as to better
validate inhibition of NFkB as a therapeutic target. (4) Investigate the
cytoplasmic effects of LMP1, including the molecular mechanisms by which LMP1
and CD40 recruit TRAFs, modify TRAFs, activate NIK and ASK, effect NIK and ASK1
interaction with downstream kinases, and continuously signal or return to a
basal state. (5) Determine the effects of LMP1 on B lymphocytes and epithelial
gene expression from the changes in RNAs following expression of LMP1, LMP1
TES1, LMP1 TES2, or LMP1 with null mutations in TES1 and TES2. The importance
of NFkB, AP1, CREB, or other factor activations will be evaluated by analyses
of relevant promoters, e.g., TRAF1, EGFR, and CD40. The effects of LMP1TES1 and
LMP1TES2 on cell gene transcription and on transformation will be compared with
the effects of LMP1 and LMP1/CD40 in transgenic mice. (6) Evaluate the role of
TRAF3 in LMP1, CD40, and LTbetaR signaling through observing differences in
RNAs with LMP1 expression or CD40 or LTbetaR activation in TRAF3 knockout
versus normal mouse cells or mice. The role of PKN in TRAF3 effects on the cell
cytoskeleton, membranes, or transcription will also be assessed. (7)
Investigate the role of C. elegans TRAF3 homologue in C. elegans neural
function so as to enable screens for interacting genes that might identify
novel TRAF functions.
No Sub Projects information available for 5R01CA085180-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01CA085180-03
Patents
No Patents information available for 5R01CA085180-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01CA085180-03
Clinical Studies
No Clinical Studies information available for 5R01CA085180-03
News and More
Related News Releases
No news release information available for 5R01CA085180-03
History
No Historical information available for 5R01CA085180-03
Similar Projects
No Similar Projects information available for 5R01CA085180-03